Successful Treatment of Prosthetic Joint Infection Due to Vancomycin-Resistant Enterococci With Tedizolid

Si, Sheng; Durkin, Michael J.; Yarbrough, Melanie L.; Liang, Stephen Y.

doi:10.1097/ipc.0000000000000469

Cited by 10 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tedizolid and linezolid showed antimicrobial and immunomodulatory properties in a murine model of hematogenous MRSA pulmonary infection 61Osteomyelitis and prosthetic joint infectionsA phase II, single-arm, open-label trial evaluating tolerability, safety, and efficacy of oral tedizolid for the treatment of bone and joint infections is ongoing (NCT03009045).A pilot study investigating tolerance, compliance, and efficacy of tedizolid for ≥6 weeks as monotherapy or in combination for orthopedic device infections caused by Gram-positive cocci is currently recruiting patients (NCT03378427).A case of successful treatment of VRE prosthetic joint infection has been reported 66Although inactive against biofilm-embedded S. aureus infection in the setting of bone and joint infections, tedizolid seems able to prevent biofilm formation 59…”

Section: Methodsmentioning

confidence: 99%

<p>Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy</p>

Bassetti¹,

Castaldo²,

Carnelutti³

et al. 2019

View full text Add to dashboard Cite

Introduction Tedizolid phosphate is an oxazolidinone approved for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) and active against methicillin-resistant Staphylococcus aureus . Aims The objective of this article was to review the evidence for the efficacy and safety of tedizolid phosphate for the treatment of ABSSSI. Evidence review Approval of tedizolid phosphate for the treatment of ABSSSI was based on the results of two phase III randomized controlled trials, ESTABLISH-1 (NCT01170221) and ESTABLISH-2 (NCT01421511), comparing 6-day once-daily tedizolid vs 10-day twice-daily linezolid. In ESTABLISH-1, noninferiority was met with early clinical response rates of 79.5% and 79.4% in tedizolid and linezolid groups, respectively (difference 0.1%, 95% CI –6.1% to 6.2%, with a 10% noninferiority margin). In ESTABLISH-2, noninferiority was met with 85% and 83% rates of early clinical response in tedizolid and linezolid groups, respectively (difference 2.6%, 95% CI –3.0% to 8.2%). Pooled data from ESTABLISH-1 and ESTABLISH-2 indicated a lower frequency of thrombocytopenia in tedizolid-treated than in linezolid-treated patients. Conclusion Tedizolid offers the option of an intravenous to oral switch, allows once-daily administration, and presents lower risk of myelotoxicity when a 6-day course is used for the treatment of ABSSSI. Greater economic cost associated with this antibiotic could be offset by its shorter treatment duration and possibility of oral administration in routine clinical practice, although either sponsored or nonsponsored postmarketing observational experience remains essential for ultimately confirming the effectiveness and tolerability of tedizolid outside clinical trials.

show abstract

Section: Methodsmentioning

confidence: 99%

<p>Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy</p>

Bassetti¹,

Castaldo²,

Carnelutti³

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Despite the potential advantages of tedizolid in osteoarticular infections (higher microbiological activity, advantageous pharmacokinetic/pharmacodynamics parameters, lower myelotoxicity, and drug–drug interactions) [ 1 , 2 , 3 ], clinical data on long-term treatment are scarce [ 16 ]. Knowledge is limited to a few experimental studies [ 17 , 18 , 19 ], case reports [ 20 ] and recently some case series in which tedizolid is prescribed for different indication including osteoarticular infections [ 21 , 22 ]. Thus, in the present study, we intend to describe our multicenter experience within the Spanish Network for Research in Infectious Diseases (REIPI) with long-term use of tedizolid in a cohort of patients with osteoarticular and diabetic foot infections and focused on the efficacy and safety in monotherapy or combination.…”

Section: Introductionmentioning

confidence: 99%

Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs

et al. 2021

View full text Add to dashboard Cite

Background: To evaluate the efficacy and safety of long-term use of tedizolid in osteoarticular infections. Methods: Multicentric retrospective study (January 2017–March 2019) of osteoarticular infection cases treated with tedizolid. Failure: clinical worsening despite antibiotic treatment or the need of suppressive treatment. Results: Cases (n = 51; 59% women, mean age of 65 years) included osteoarthritis (n = 27, 53%), prosthetic joint infection (n = 17, 33.3%), and diabetic foot infections (n = 9, 18%); where, 59% were orthopedic device-related. Most frequent isolates were Staphylococcus spp. (65%, n = 47; S. aureus, 48%). Reasons for choosing tedizolid were potential drug-drug interaction (63%) and cytopenia (55%); median treatment duration was 29 days (interquartile range -IQR- 15–44), 24% received rifampicin (600 mg once daily) concomitantly, and adverse events were scarce (n = 3). Hemoglobin and platelet count stayed stable throughout treatment (from 108.6 g/L to 116.3 g/L, p = 0.079; and 240 × 109/L to 239 × 109/L, p = 0.942, respectively), also in the subgroup of cases with cytopenia. Among device-related infections, 33% were managed with implant retention. Median follow-up was 630 days and overall cure rate 83%; among failures (n = 8), 63% were device-related infections. Conclusions: Long-term use of tedizolid was effective, showing a better safety profile with less myelotoxicity and lower drug-drug interaction than linezolid. Confirmation of these advantages could make tedizolid the oxazolidinone of choice for most of osteoarticular infections.

show abstract

“…However, there is medical necessity in the treatment of other infections caused by MDR organisms and in these cases, novel antibiotics are frequently used ‘off-label’. Some examples are the use of ceftaroline for endocarditis, 10 11 tedizolid for osteomyelitis 12 and ceftolozane/tazobactam for pneumonia, 13 intravascular infections 14 or patients with cystic fibrosis. 15 This type of use may lead to improved outcomes in patients when they are really needed, but also to increased rates of unexpected adverse events, faster development of resistance and higher acquisition costs.…”

Section: Introductionmentioning

confidence: 99%

Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project

et al. 2020

View full text Add to dashboard Cite

IntroductionCeftaroline, tedizolid, dalbavancin, ceftazidime-avibactam and ceftolozane-tazobactam are novel antibiotics used to treat infections caused by multidrug-resistant pathogens (MDR). Their use should be supervised and monitored as part of an antimicrobial stewardship programme (ASP). Appropriate use of the new antibiotics will be improved by including consensual indications for their use in local antibiotic guidelines, together with educational interventions providing advice to prescribers to ensure that the recommendations are clearly understood.Methods and analysisThis study will be implemented in two phases. First, a preliminary historical cohort (2017–2019) of patients from 13 Andalusian hospitals treated with novel antibiotics will be analysed. Second, a quasiexperimental intervention study will be developed with an interrupted time-series analysis (2020–2021). The intervention will consist of an educational interview between prescribers and ASP leaders at each hospital to reinforce the proper use of novel antibiotics. The educational intervention will be based on a consensus guideline designed and disseminated by leaders after the retrospective cohort data have been analysed. The outcomes will be acceptance of the intervention and appropriateness of prescription. Incidence of infection and colonisation with MDR organisms as well as incidence ofClostridioides difficileinfection will also be analysed. Changes in prescription quality between periods and the safety profile of the antibiotics in terms of mortality rate and readmissions will also be measured.Ethics and disseminationEthical approval will be obtained from the Andalusian Coordinating Institutional Review Board. The study is being conducted in compliance with the protocol and regulatory requirements consistent with International Council of Harmonisation E6 Good Clinical Practice and the ethical principles of the latest version of the Declaration of Helsinki. The results will be published in peer-reviewed journals and disseminated at national and international conferences.Trial registration numberNCT03941951.

show abstract

Successful Treatment of Prosthetic Joint Infection Due to Vancomycin-Resistant Enterococci With Tedizolid

Abstract: Few antibiotic options exist for the management of infections due to vancomycin-resistant enterococci (VRE). We describe a case involving the safe and successful use of tedizolid, a new oxazolidinone, to treat VRE prosthetic joint infection.

Cited by 10 publications

References 12 publications

<p>Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy</p>

<p>Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy</p>

Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs

Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project

Contact Info

Product

Resources

About